BioNTech Faces Mixed Analyst Views, FDA Fast-Track Designation, and Leadership Transition
BioNTech faces mixed analyst views as Bernstein initiates with a cautious Market Perform rating, while the company secures FDA Fast Track designation for BNT113 and prepares for a shareholder vote on capital restructuring and leadership transition.